Your browser doesn't support javascript.
loading
NDMA analytics in metformin products: Comparison of methods and pitfalls.
Fritzsche, Matthias; Blom, Giorgio; Keitel, Judith; Goettsche, Anja; Seegel, Maic; Leicht, Stefan; Guessregen, Brunhilde; Hickert, Sebastian; Reifenberg, Philipp; Cimelli, Alexandra; Baranowski, Romane; Desmartin, Emmanuel; Barrau, Elodie; Harrison, Mark; Bristow, Tony; O'Neill, Nicholas; Kirsch, Annette; Krueger, Phillip; Saal, Christoph; Mouton, Bruno; Schlingemann, Joerg.
Afiliação
  • Fritzsche M; Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany.
  • Blom G; Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, United Kingdom.
  • Keitel J; Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany.
  • Goettsche A; Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany.
  • Seegel M; Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany.
  • Leicht S; Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany.
  • Guessregen B; Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany.
  • Hickert S; Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany.
  • Reifenberg P; Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany.
  • Cimelli A; Eurofins-Amatsi Analytics, Parc de Genibrat, Fontenilles 31470, France.
  • Baranowski R; Eurofins-Amatsi Analytics, Parc de Genibrat, Fontenilles 31470, France.
  • Desmartin E; Eurofins-Amatsi Analytics, Parc de Genibrat, Fontenilles 31470, France.
  • Barrau E; Eurofins-Amatsi Analytics, Parc de Genibrat, Fontenilles 31470, France.
  • Harrison M; Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, United Kingdom.
  • Bristow T; Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, United Kingdom.
  • O'Neill N; Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, United Kingdom.
  • Kirsch A; Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany.
  • Krueger P; Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany.
  • Saal C; Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany.
  • Mouton B; Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany.
  • Schlingemann J; Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany. Electronic address: joerg.schlingemann@merckgroup.com.
Eur J Pharm Sci ; 168: 106026, 2022 Jan 01.
Article em En | MEDLINE | ID: mdl-34597792
BACKGROUND: For nearly three years, the concerns regarding trace levels of N-nitrosamines in pharmaceuticals and the associated cancer risk have significantly expanded and are a major issue facing the global pharmaceutical industry. N-nitrosodimethylamine (NDMA) found in formulations of the popular anti-diabetic drug metformin is a prominent example. This has resulted in product recalls raising the profile within the media. Issues of method robustness, sample preparation and several unexpected sources of nitrosamine contamination have been highlighted as false positive risks. It has become apparent that the identification of the root causes of artefactual formation of nitrosamines must be identified to mitigate risk associated with the analysis. METHODS: A comparison study between four laboratories, across three companies was designed, employing orthogonal mass spectrometric methods for the quantification of NDMA in two metformin immediate release (IR) formulations and one extended release (XR) formulation. These were 2x LC-MS/MS, GC-MS/MS and GC-HRMS. RESULTS: Good agreement of results was obtained for the IR formulations. However, we measured higher concentrations of NDMA in the XR formulation using GC-MS/MS compared to LC-MS/MS. We could show that this was due to artefactual (in situ) formation of NDMA when samples were extracted with dichloromethane. Removal of dimethylamine (DMA) and nitrite from the extracted sample or the addition of a nitrosation scavenger are shown to be effective remedies. NDMA in situ formation was not observed in 10% MeOH or acetonitrile. CONCLUSION: Metformin pharmaceuticals contain traces of the API impurity DMA as well as inorganic nitrite from excipients. This can lead to artefactual formation of NDMA and hence false positive results if DCM is used for sample extraction. Similar artefacts are likely also in other pharmaceuticals if these contain the secondary amine precursor of the respective nitrosamine analyte.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dimetilnitrosamina / Metformina Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dimetilnitrosamina / Metformina Idioma: En Ano de publicação: 2022 Tipo de documento: Article